Welcome to your daily round-up of everything happening in the world of neurorehabilitation.
Research news
Heart disease and stroke in women of all ages
The Journal of the American Heart Association’s 2024 Go Red for Women issue has highlighted new findings and progress in research on women and cardiovascular disease. Topics in the issue include the impact of sedentary behavior on heart disease risk in older women; sex differences in the relationship between schizophrenia and the development of heart disease; and maternal dietary patterns and risk of preeclampsia.
Abdominal fat and Alzheimer’s risk in individuals
A new study has shown that middle-aged individuals with a family history of Alzheimer’s disease, the amount of fat in their abdominal organs is related to their brain volumes and cognitive function, highlighting the importance of investigating the interrelationships of fat depots, brain aging and cognition in the context of sex differences.
Link between health care disparities and stroke treatment
A new study has shown that social factors can influence whether or not someone receives stroke treatment in England, factors including income, education, employment, and social status. The researchers states that reducing these disparities requires interventions to improve the quality of acute stroke care and address disparities in cardiovascular risk factors present before stroke.
Company news
Alzheon: Biomarker, brain preservation, and clinical results
Alzheon, Inc., a clinical-stage biopharmaceutical company developing a portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease and related neurodegenerative disorders, has announced its participation in the upcoming International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders in Lisbon, Portugal from March 5–9, 2024.
MHRA issues notice of acceptance for Phase 3 Early Alzheimer’s Disease Trial
AriBio Co. has confirmed it has received Notice of Acceptance for POLARIS-AD, a Phase 3 early Alzheimer’s disease clinical trial from the Medicines and Healthcare Products Regulatory Agency in the UK. The MHRA completed their review on the 21 of February and confirmed a favorable ethical opinion. The company has stated it expects to initiate the clinical trial before the end of Q1’2024 in the UK.
Curve Therapeutics raises £40.5 million
Curve Therapeutics has announced the close of its successful £40.5 million Series A financing. Pfizer Ventures led the round with participation from Columbus Venture Partners and British Patient Capital, which join founding investor Advent Life Sciences and co-lead from the seed round, Epidarex Capital. The company has a US$1.7bn global research collaboration with MSD the trade name of Merck & Co., Inc., Kenilworth, NJ USA, to discover and validate modulators of up to five therapeutic targets using its Microcycle technology, initially for oncology and neurology indications.
Technology
Neurotechnology and payments
Finance Magnates explores how Brain-Computer Interfaces (BCIs) are positioning themselves a transformative force poised to revolutionise user experiences, fortify security measures, and amplify accessibility in the digital payments domain.
Pioneering the future of neurotechnology
BNN looks at how Stéphanie Lacour is revolutionising neuroprosthetic technology and shaping the future of neurotechnology, exploring the potential benefits and ethical implications of merging neuroscience and technology.
